Acumen Pharmaceuticals (ABOS) Accounts Payables (2020 - 2026)

Acumen Pharmaceuticals has disclosed Accounts Payables across 7 years of filings, most recently posting $13.4 million for Q2 2026.

• In Q2 2026, Accounts Payables rose 536.19% year-over-year to $13.4 million; the TTM figure through Jun 2026 stood at $13.4 million (up 536.19% YoY), while the FY2025 annual figure was $554000.0, down 90.19% from the prior year.
• Accounts Payables came in at $13.4 million for Q2 2026 at Acumen Pharmaceuticals, up from $1.7 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $13.4 million in Q2 2026 to a low of $554000.0 in Q4 2025.
• Average Accounts Payables over 5 years is $2.6 million, with a median of $1.7 million recorded in 2022.
• Year-over-year, Accounts Payables tumbled 90.19% in 2025 and jumped 536.19% in 2026.
• Over 5 years, Accounts Payables stood at $1.6 million in 2022, then decreased by 15.91% to $1.4 million in 2023, then jumped by 309.57% to $5.6 million in 2024, then plunged by 90.19% to $554000.0 in 2025, then surged by 2314.98% to $13.4 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $13.4 million in Q2 2026, $1.7 million in Q1 2026, and $554000.0 in Q4 2025.